Would the incorporation of CellPryme-M into the manufacturing of an already approved (or clinically advanced) cell therapy product send that product back to phase 1 clinical trials?
If so, CellPryme-M may only be attractive to pre-clinical or phase 1 assets.
Anyone able to answer this question? If not, I'll email the company.
- Forums
- ASX - By Stock
- PTX
- CellPryme-M question
CellPryme-M question
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PTX (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.3¢ |
Change
0.001(1.92%) |
Mkt cap ! $42.68M |
Open | High | Low | Value | Volume |
5.4¢ | 5.4¢ | 5.2¢ | $21.85K | 418.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 45278 | 5.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.4¢ | 8500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 45278 | 0.052 |
2 | 139215 | 0.051 |
6 | 251003 | 0.050 |
3 | 101666 | 0.048 |
1 | 50000 | 0.047 |
Price($) | Vol. | No. |
---|---|---|
0.054 | 8500 | 1 |
0.055 | 147258 | 2 |
0.056 | 98076 | 2 |
0.057 | 216805 | 3 |
0.058 | 115230 | 2 |
Last trade - 10.48am 30/04/2024 (20 minute delay) ? |
|
|||||
Last
5.3¢ |
  |
Change
0.001 ( 1.92 %) |
|||
Open | High | Low | Volume | ||
5.3¢ | 5.3¢ | 5.2¢ | 37682 | ||
Last updated 11.01am 30/04/2024 ? |
Featured News
PTX (ASX) Chart |